Neuro-inflammation biotech Jupiter Neurosciences revives $12 million IPO with revised terms

Retrieved on: 2024-07-12 22:21:03

Tags for this article:

Click the tags to see associated articles and topics

Neuro-inflammation biotech Jupiter Neurosciences revives $12 million IPO with revised terms. View article details on hiswai:

Excerpt

Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday.

Article found on: www.renaissancecapital.com